Skip to content

CMS confirms Flatiron Assist™ clinical guidelines meet requirements of the Enhancing Oncology Model


April 2023

CMS confirms Flatiron Assist™ clinical guidelines meet requirements of the Enhancing Oncology Model

Flatiron Health is proud to announce that the Centers for Medicare & Medicaid Services (CMS) has confirmed that Flatiron Assist™ clinical guidelines meet the requirements of the upcoming Enhancing Oncology Model (EOM). With this confirmation, cancer centers participating in EOM will be able to use Flatiron Assist as an evidence-based guideline in accordance with the EOM participant redesign.

Flatiron Assist leverages guidelines from the National Comprehensive Cancer Network® (NCCN®) to deliver personalized, evidence-based clinical decision support to oncologists.  Flatiron Assist surfaces NCCN Guidelines® for 25 diseases, covering 90% of all orders. Clinical guidelines in Flatiron Assist are continually updated to ensure oncologists have access to the latest information, including new biomarkers to help identify the most appropriate precision cancer treatments for patients. Cancer centers can also build custom pathways to meet organizational or payer preferences.

EOM requires the use of evidence-based guidelines, alongside more robust care planning and the use of data for ongoing quality improvement, to improve cancer outcomes and patient experiences. Flatiron Assist clinical guidelines can be used by model participants in support of this requirement.

“We are excited to be a part of the next generation of cancer care by partnering with cancer centers participating in EOM,” said James Hamrick, MD, MPH, VP of Clinical Oncology at Flatiron Health. “Evidence-based guidelines are foundational for improving the delivery of care, and the right technologies can make it less burdensome and more intuitive to consult these guidelines at the point of care.”

Flatiron Assist has a track record of success in the oncology space, with 80% clinician adoption, over 90% NCCN® concordance, and a 58% reduction in unique regimens ordered across cancer centers.

“Our mission is to make it easy to drive value with every decision while treating every patient as a unique individual who deserves access to the best care available,” said Hamrick.  “With continually updated NCCN guidelines, as well as access to information about clinical trial opportunities and features to streamline prior authorization, Flatiron Assist provides exactly what oncologists need to deliver high quality, high value care for the best possible patient outcomes.”

Your evidence-based, oncology-specific clinical decision support tool

Learn how Flatiron Assist™ supports clinical decisions in oncology.